Jesse Neil is a veteran healthcare attorney whose experience helps clients bridge two complex worlds — healthcare operations and public policy. Clients value his deep understanding of the challenges providers face in a constantly evolving regulatory environment. Jesse strives to serve as a strategic partner who can help healthcare clients leverage opportunities quickly and effectively. His public policy experience further enables him to advise clients on how to adapt operations to the current regulatory landscape and help them understand and plan for regulatory developments, emerging trends, and other market factors.
Jesse is widely known for his experience with hospitals, health systems, and ancillary service lines including behavioral health and outpatient services. He assists healthcare clients with compliance issues related to EMTALA, the federal Stark Law and Anti‐Kickback Statute, as well as state regulations. He is also an experienced advocate for healthcare providers facing government investigations and enforcement actions.
Prior to joining Waller, Jesse spent nearly a decade as a member of the in‐house legal team at one of the largest publicly‐traded hospital companies in the United States. As lead counsel for one of the company’s three operating divisions, Jesse provided day‐to‐day guidance to corporate departments, hospitals, clinics, and ancillary service providers throughout the country. He collaborated with operational and clinical leadership to develop network alignment strategies by negotiating a wide range of transactions, employment agreements, and other contractual arrangements with providers. Jesse also worked with a multidisciplinary team to manage the company’s public policy advocacy strategy. In this role, he monitored federal and state policy developments and implemented engagement strategies with government and industry stakeholders.
Previously, Jesse served as Assistant Attorney General for the Office of the Tennessee Attorney General. He led investigations into healthcare entities and pharmaceutical companies with respect to compliance with fraud and abuse statutes.